Datascope
This article was originally published in The Gray Sheet
Executive Summary
FDA requests additional information for the firm's VasoSeal premarket approval application, which seeks clearance of the device for facilitating hemostasis following angiography. According to the firm, FDA is asking for more data on the "clinical utility" of the device, "in light of the company's August 1993 amendment" that dropped a proposed angioplasty indication. FDA told Datascope that clinical utility could be demonstrated if the firm broadened the claims or indications for the device and provided supporting data. The Vasoseal PMA was submitted in February 1992 and filed by FDA two months later ("The Gray Sheet" Sept. 6, 1993, p. 10)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.